1537191-01-7

Upstream product

• 111-24-0 1,5-dibromo-pentane 

Downstream Products

• 1537191-14-2 C₃₅H₃₅N₅O₄ReS⁽¹⁺⁾*Cl^(1-) 

Relevant academic research and scientific papers

2-Phenylbenzothiazole conjugated with cyclopentadienyl tricarbonyl [CpM(CO)3] (M = Re, 99mTc) complexes as potential imaging probes for β-amyloid plaques

Technetium-99m-labeled cyclopentadienyl tricarbonyl complexes conjugated with the 2-phenylbenzothiazole binding motif were synthesized. The rhenium surrogates 20, 21, 22 and 23 were demonstrated to have moderate to high affinities for Aβ1-42 aggregates with Ki values of 142, 76, 64 and 24 nM, respectively. During the fluorescence staining of brain sections of transgenic mice and patients with Alzheimer's disease, these rhenium complexes demonstrated perfect and intense labeling of Aβ plaques. Moreover, in in vitro autoradiography, 99mTc-labeled complexes clearly detected β-amyloid plaques on sections of brain tissue from transgenic mice, which confirmed the sufficient affinity of these tracers for Aβ plaques. However, these compounds did not show desirable properties in vivo, especially showing poor brain uptake (below 0.5% ID g-1), which will hinder the further development of these tracers as brain imaging agents. Nonetheless, it is encouraging that these 99mTc-labeled complexes designed by a conjugate approach displayed sufficient affinities for Aβ plaques. This journal is

N2S2 series 2-arylbenzothiazole compound with high affinity to Abeta plaques, and preparation method and application thereof

The invention provides an N2S2 series 2-arylbenzothiazole compound with high affinity to Abeta plaques, and a preparation method and an application thereof. The structure of the compound is represented by formula (I) shown in the description; and in the formula (I), M is Re or Tc, X is CH or N, R is H or CH3, and Y is -(CH2)No- (n is an integer in a range of 3-6) or -(CH2CH2O)n- (n is 2 or 3). In-vivo and in-vitro experiments show that most like molecules have high affinity to Abeta1-42 aggregates, can specifically bind to the Abeta plaques of brain slices of transgenic mice and AD patients, parts of Tc labeled developers have high initial brain uptake and fast brain clearing rate in normal mice, and have potential to be developed into new Abeta plaque SPECT developers used for AD early clinic diagnosis.

99mTc-Labeled 2-Arylbenzothiazoles: Aβ Imaging Probes with Favorable Brain Pharmacokinetics for Single-Photon Emission Computed Tomography

A series of 2-arylbenzothiazole derivatives conjugated with bis(aminoethanethiol) (BAT) chelating groups were designed and synthesized. A competitive binding assay-based screening was used to select seven rhenium complexes with potent binding affinity toward Aβ1-42 aggregates (Ki 99mTc labeling and further evaluation. The 99mTc-labeled probes showed good affinity and specificity to Aβ plaques in Tg mouse brain tissue in in vitro autoradiography studies. Moreover, [99mTc]14b exhibited favorable brain pharmacokinetics in normal mice (2.11% ID/g at 2 min and 0.62% ID/g at 60 min). Ex vivo autoradiography revealed extensive labeling of Aβ plaques by [99mTc]14b in the brain of Tg mice. Furthermore, we performed the first single-photon emission computed tomography (SPECT) imaging study in nonhuman primates with 99mTc-labeled Aβ probes. The semiquantitative data showed that [99mTc]14b penetrated the brains of rhesus monkeys. These results indicate that [99mTc]14b could be utilized as a SPECT imaging probe for Aβ plaques.

Plaque A β having affinity with the 2-aryl benzo thiazole compound, preparation method and application thereof

The invention provides a 2-aryl benzothiazole compound with high affinity with A(beta) plaque and a preparation method and application thereof. The structure of the compound is shown by formula (I). In-vitro competitive binding experiments indicate that the kind of molecules have medium affinity with the A(beta) 1-42 aggregate; in-vitro autoradiography experiments indicate that the molecules marked by Tc-99m can be combined with the A(beta) plaque in blood vessels of the brain with specificity and high affinity; in-vivo bio-distribution experiments on a normal mice indicate that a developer partially marked by Tc-99m has the advantages of low initial brain extraction, fast blood removal and the like, and is expected to become a new single-photon A(beta) plaque developer for early-stage clinical diagnosis of CAA (cerebral amyloid angiopathy) or AD (Alzheimer's disease).

99mTc-labeled benzothiazole and stilbene derivatives as imaging agents for Aβ plaques in cerebral amyloid angiopathy

β-Amyloid (Aβ) plaques in the blood vessels of the brain are associated with cerebral amyloid angiopathy (CAA), which is a common cause of stroke and vascular diseases. Imaging agents that can differentiate between Aβ plaques in the brain and those on the walls of cerebrovascular vessels will provide non-invasive biomarkers to interrogate the pathogenesis of CAA and give insights into the mechanisms, significance and impact of Aβ-CAA for developing effective therapies for CAA and stroke. A new series of 99mTc-labeled benzothiazole and stilbene derivatives with positive charge were developed and evaluated for selectively targeting Aβ plaques in the blood vessels of the brain. The rhenium complexes 6, 7, 13 and 14 displayed medium binding affinity to Aβ1-42 aggregates with Ki values of 162, 37, 366 and 78 nM, respectively. In vitro fluorescence staining of 7 and 14 demonstrated an intense labeling of Aβ plaques associated with blood vessel walls on brain sections of a patient with Alzheimer's diseases. A relatively low initial brain uptake for [99mTc]7 and [ 99mTc]14, 0.18 and 0.24 ID% per gram, respectively, suggests that they may be useful SPECT imaging agents for selectively detecting Aβ plaques associated with cerebral vessels in the living human brain.